Canada has a growing biotechnology sector focused on developing treatments for neurodegenerative diseases, particularly Alzheimer's Disease and Parkinson's Disease. Canadian companies combine strong academic research partnerships with innovative R&D programs targeting various disease mechanisms including amyloid-beta accumulation, tau pathology, alpha-synuclein aggregation, mitochondrial dysfunction, and neuroinflammation.
The Canadian neurotechnology ecosystem benefits from significant government funding through agencies like CIHR[1], Brain Canada[2], and the Ontario Brain Institute[3], as well as world-class research institutions including the McGill Centre for Studies in Aging[@mcgill], University of Toronto's Krembil Research Institute, and the University of British Columbia's Djavid Mowafaghian Centre for Brain Health.
Cognicann[4] is a Canadian biotechnology company focused on developing innovative therapies for neurodegenerative diseases. Based in Vancouver, British Columbia, the company targets Alzheimer's Disease and cognitive impairment through novel small molecule therapeutic approaches. See the Cognicann organization page for more details.
Neuralstem is a biotechnology company focused on stem cell therapies for neurological disorders, with research collaborations in Canada. The company explores cell replacement approaches for Alzheimer's Disease and Parkinson's Disease using neural stem cell transplantation.
Anavex Life Sciences[5] is a clinical-stage biopharmaceutical company developing novel drug candidates for the treatment of neurodegenerative diseases, with Canadian research partnerships. The company's lead compound ANAVEX2-73 (blacimesine) is a Sigma-1 receptor agonist that has demonstrated promise in modulating endoplasmic reticulum stress and neuroinflammation pathways relevant to Alzheimer's Disease.
BioArctic AB is a Swedish biopharma company with Canadian partnerships focused on Alzheimer's Disease. The company is known for its work on lecanemab (LEQEMBI), developed in partnership with Eisai, which targets amyloid-beta protofibrils.
Cantoxi is a Canadian biotech focused on mitochondrial dysfunction in neurodegeneration. The company's approach targets mitochondrial protective mechanisms that are compromised in both Parkinson's Disease and ALS.
Treventis[6] is a Canadian company developing treatments for Alzheimer's Disease. The company focuses on tau aggregation inhibition, targeting the pathological misfolding of tau protein that leads to neurofibrillary tangles in Alzheimer's disease brains. See the Treventis Corporation organization page for more details.
ProMIS Neurosciences[7] is a Canadian biotech company focused on developing monoclonal antibodies for toxic oligomers in neurodegenerative diseases. The company's proprietary platform identifies disease-specific conformational targets on proteins like amyloid-beta and alpha-synuclein. See the ProMIS Neurosciences organization page for more details.
Xenon Pharmaceuticals[8] is a Vancouver-based biotech company with emerging programs in neuroscience. While primarily known for epilepsy programs, Xenon has explored ion channel targets relevant to neurodegeneration and neuronal excitability.
Inverseon is a biotech company with Canadian operations developing treatments for CNS disorders. The company leverages novel drug delivery technologies to improve CNS penetration of therapeutic compounds targeting Alzheimer's Disease and Parkinson's Disease.
Intellect Neurosciences has Canadian research partnerships focused on antibody therapeutics for Alzheimer's Disease. The company develops monoclonal antibodies targeting disease-relevant proteins.
Hylax Therapeutics is a Canadian company focused on novel therapeutics for neurodegeneration. Based in Calgary, the company develops small molecule modulators targeting disease mechanisms.
Canada's universities are a major source of neurodegeneration biotech innovation, with active technology transfer offices and research hospitals driving spin-out companies.
CIHR is Canada's premier health research funding agency, supporting neurodegeneration research through multiple institutes:
The Ontario Brain Institute funds integrated research networks focused on brain disorders including Alzheimer's Disease and Parkinson's Disease, supporting both academic research and company formation.
Brain Canada Foundation provides national funding for neuroscience research through the Canada Brain Research Fund, supporting cross-institutional collaborations in neurodegeneration.
Funds patient-oriented research and supports clinical trial networks across Canadian institutions.
Canada hosts numerous clinical trial sites for neurodegenerative disease therapies, benefiting from:
Active trial areas include:
Canadian companies and researchers actively collaborate with: